Targeting the IL-12/IL-23 cytokine family in the treatment of psoriatic disease

Expert Review of Dermatology

Volumn 3, Issue 4, 2008, Pages 453-463

  Vergou, Theognosia ^a   Lima, Xinaida Taligare Vasconcelos ^a   Kimball, Alexandra Boer ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

ABT 874; Anti IL 12 23 antibody; CNTO 1275; IL 12; IL 23; Interleukin; Psoriasis; Ustekinumab

Indexed keywords

ABT 874; ADALIMUMAB; ALEFACEPT; AURANOFIN; CALCITRIOL; CNTO 1275; CYCLOSPORIN A; CYTOKINE; ETANERCEPT; FUMARIC ACID ETHYL ESTER; IMMUNOLOGIC AGENT; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 12P40; INTERLEUKIN 23; PLACEBO; RETINOID DERIVATIVE; STA 5326; UNCLASSIFIED DRUG;

ANAPHYLAXIS; APOPTOSIS; BASAL CELL CARCINOMA; CARDIOVASCULAR DISEASE; CELLULITIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; HEADACHE; HEART DISEASE; HEART INFARCTION; HUMAN; IMMUNOPATHOGENESIS; INFECTION; INJECTION SITE REACTION; OPPORTUNISTIC INFECTION; OVARY CANCER; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FAMILY; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REVIEW; RHINOPHARYNGITIS; SALMONELLOSIS; SERUM SICKNESS; SINGLE DRUG DOSE; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; TUBERCULOSIS; ULTRAVIOLET B RADIATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 55449093745     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/17469872.3.4.453     Document Type: Review

References (48)

1. Lebwohl M, Psoriasis. Lancet 361, 1197-1204 (2003).
2. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive and is associated with widespiread treatment dissatisfaction. J. Investig. Dermatol. Symp. Proc. 9, 136-139 (2004)
3. Hueber AJ, McInnes IB. Immune regulalion in psoriasis and psoriatic arthritis - recent developments. Immunol. Lett. 114, 59-65 (2007).
4. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesk of Psoriasis Provide new therapeutic opportunities. J. Clin. Invest. 113, 1664-1615 (2004).
5. Kimball AB, Kupper TS. Future perspectives/quo vadis psoriasis treatment? Immunology, pharmacogenomics, and epidemiology. Clin. Dermatol. (2007) (In press).
6. Eedy DJ, Burrows D, Bridges JM, Jones FG. Clearance of severe psoriasis after allogenic bone marrow transplantation. BMJ 300, 1398-1399 (1990).
7. Snowden JA, Heaton DC. Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive autoimmunity. Br. J. Dermatol. 137, 130-132 (1997).
8. Bos JD, de Rie MA, Teunissen MB, Piskin G. Psoriasis: dysregulation of innate immunity, Br. J. Dermatol. 152, 1098-1107 (2005).
9. Trinchieri G, Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133-146 (2003)
10. Kobayashi M, Fitz L, Ryan M et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170, 827-846 (1989).
11. Torti DC, Feldman SR. Interleukin-12, interleukin-23 and psoriasis. J. Am. Acad. Dermatol. 57. 1059-1068 (2007).
12. Gately MK, Renzetti LM, Magram J et al. The interleukin-12/ interleukin-12 receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 16, 495-521 (1998).
13. Hong K, Chu A, Lúdviksson BR, Berg EL, Ehrhardt RO. IL-12, independently of IFN-γ, plays a Crucial role in the pathogenesis of a mourine psoriasis-like skin disorder. J. Immunol. 162, 7480-7491 (1999).
14. Economidou J, Barkis J, Demetriou Z et al. Effects of cyclosporin-A on immune activation markets in patients with active psoriasis. Dermatology 199, 144-148 (1999).
15. Shaker OG, Moustafa W, Essmat S, Abdel-Halim M, El-Komy M. The role of interleukin-12 in the pathogenesis of psoriasis. Clin. Biochem. 39, 119-125 (2006).
16. Rosmarin D. The potential of interleukin 12 inhibition the treatment of psoriasis. J. Drugs Dermatol. 4, 318-325 (2005).
17. Bowman EP, Chacketian AA, Cua DJ. Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy. Curr. Opin. Infect. Dis. 245-252 (2006).
18. Chen Z, O'Shea JJ. Th17 celis: a new fate for differentianng helper T cells. Immunol. Res. DOI: 10.1007/s12026-007-8014-9 (2008) (Epub ahead of print).
19. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278, 1910-1914 (2003).
20. Piskin G, Sylva-Steenland. RM, Bos JD, Teunissen MBM. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced express in psoriasis skin. J. Immunol. 176, 1908-1915 (2006).
21. Lowes MA, Kikuchi T, Fuentes-Duculan J et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest. Dermatol. 128, 1207-1211 (2008).
22. Lee E, Trepicchio WL, Oestreicher JL et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199, 125-130 (2004).
23. Ma HL, Liang S, Li J et al. IL-22 is required for Th17 Cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J. Clin. Invest. 118(2), 597-607 (2008).
24. D'Ambrosio D, Cippitelli M, Cocciolo MG et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3-involvement of NF-κB downregulation in transcriptional repression of the P40 gene. J. Clin. Invest. 101(1). 252-262 (1998).
25. + T cells from the Th1 to the Th2 pathway. Br. J. Pharmacol. 134(1), 571-578 (2001).
26. Litjens NH-Rademaker M, Ravensbergen B et al. Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur. J. Immunol. 34 (2), 565-575 (2004).
27. Piskin G, Tursen U, Sylva-Steenland RM, Bos JD, Teunissen MB. Clinical improvement in chronic plaque-type. psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN- inducers - IL-12, IL-18 and IL-23. Exp. Dermatol. 13, 764-772 (2004).
28. Shen C, Assche GV. Colpaert S et al. Adalimumab induces apoptosis of human monocytes: a comparitive study with infliximab and etanercept. Aliment Pharmacol. Ther. 21, 251-258 (2005).
29. Kageyama Y, Ichikawa T, Nagafusa T, Torikai E, Shimazu M, Nagano A. Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3α in patients with rheumatoid arthritis. Rheumatol Int. 28, 137-143 (2007).
30. Chamian F, Lowes MA, Lin SL. et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc. Natl. Acad. Sci. USA 102, 2075-2080 (2005).
31. Tada Y, Asahina A, Takekoshi T et al. Interleukin 12 production by monocytes from patient, with psoriasis and its inhibition by cyclosperin A. Br J. Dermatol, 154, 1180-1183 (2006).
32. Na SY, Kang BY, Chung SW et al. Retinoids inhibit interleukin-12 production in macrophages through physical association of retinoid X receptor and NFκB. J. Biol. Chem. 274(12), 7674-7680 (1999).
33. De Jong R, Altare F, Haagen IA et al. Severe mycobacterial and Salmonella infections interleukin-12 receptor-deficient patients. Science 280, 1435-1438 (1998).
34. Cooper AM, Solache A. Khader SA. Interleukin-12 and tuberculosis: an old story revisited. Curr. Opin. Immunol. 19, 441-447 (2007).
35. MacLennan C. Ficschl C, Lammas DA et al. Interleukin (IL)-12 and IL-23 are key cytokines for immunity against Salmonella in humans. J. Infect. Dis. 190. 1755-1757 (2004).
36. Bustamante J, Boisson-Dupuis S, Jouanguy E et al. Novel primary immunodeficiencies revealed by the investigation of paediatric infectious diseases. Curr. Opin. Immunol. 20, 39-48 (2008).
37. Reddy M, Davis C, Wong J, Marsters P, Pendley C, Prabhakar U. Modulation of CLA, IL-12R, CD40L, and IL-2Rα expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275. Cell Immunol. 247, 1-11 (2007).
38. Kauffman CL, Aria N, Toichi E et al. A Phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J. Invest. Dermatol. 123, 1037-1044 (2004).
39. Toichi E, Torres G, McCormick TS et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines and IL-12/IL-23 in psoriasis. J. Immunol. 177, 4917-4926 (2006).
40. Krueger G, Langley RG, Leonardi C et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356, 580-592 (2007).
41. Clark LN, Lebwohl M. Recent advances in medical dermatology. Int. J. Dermatol. 46, 1005-1010 (2007).
42. Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safecy of ustekinumab, a human interleukin-12/23 monoclonal antibody, in psoriasis patients: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 3771, 1665-1674 (2008).
43. Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371, 1675-1684 (2008).
44. Ciocon DH, Kimball AB. Psoriasis and psoriatic arthritis: separate or one and the same? Br. J. Dermatol. 157, 850-860 (2007).
45. Gottlieb AB, Mencer A, Mendelsohn A et al. Phase II randomized, placebo controlled study of CNTO 1275, a human interleukin-12/23 monoclonal antibody, in psoriatic arthritis. Presented at: American College of Rheumatology Meeting. Boston, MA, USA, 7-11 November 2007.
46. Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, Phase II trial. Arch. Dermatol. 144(2), 200-207 (2008).
47. Billich A. Drug evaluation: apilimod, an oral IL-12/IL-23 inhibiuor for the treatment of autoimmune diseases and common variable immunodeficiency. IDrugs 10(1), 53-59 (2007).
48. Gordon K, Tschen E, Korman N et al. A Phase II study of STA-5326, an oral IL12 and IL3 inhibitor, in patients with moderate-to-severe chronic plaque psoriasis (CPP). Presented at: 4th International Congress. The Royal College of Physicians, London, UK, 1-3 December 2005.